Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5031) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31 deletion: Results of the multicenter MDS-003 Study.
Reviewer: Christopher Dolinsky, MD
University of Pennsylvania School of Medicine
Ultima Vez Modificado: 16 de mayo del 2005
Translation for this article does not exist